Mean weight loss favored semaglutide 7.2 mg (18.7%) over 2.4 mg (15.6%) and placebo (3.9%), with more gastrointestinal toxicity and increased dysaesthesia at 7.2 mg
That distinction matters for patients tracking Mounjaro and Zepbound, which contain tirzepatide rather than semaglutide and are not affected by the current generic approvals
Participants on lower-to-moderate doses experienced 812% body weight loss, translating to roughly 1525 pounds for a 180-pound individualmeaning a 10-pound goal falls well within demonstrated safety and efficacy ranges
Blood samples (100 L each) were collected from mice via cardiac puncture and allowed to clot at room temperature for 30 min
Until now, there have been no robust, peer-reviewed, clinical trials that ensure the safety, efficacy, and long-term outcomes of microdosing GLP-1 medications